Overview
LabGenius develops next-generation protein therapeutics using a machine learning-driven evolution engine (EVA).
They use robotic automation, Engineering Biology and advanced machine learning to explore protein fitness landscapes and improve multiple drug properties simultaneously. They are a privately-owned company, backed by top-tier venture capital funds, currently based in London.
They are initially deploying EVA to develop novel therapeutics with distinct advantages over traditional methods. In the first instance, they’re going after Inflammatory Bowel Disease (IBD). Today, protein- based IBD treatments generate billions in annual revenue, yet they are far from perfect. They’re working on a new class of protein-based IBD treatments that have the potential to be more convenient, more effective, and safer than existing options.
Our Support
SynbiCITE Support
- London Biofoundry Support
- PoC funding
- Lean Launchpad Training
- Biostart Accelerator – participant
